A new AI model from Meta allows users to create realistic deepfakes of regular people and celebrities using public Instagram photos as source material — and the company’s AI detection tool doesn’t ...

Muse Image, which can create realistic images for users on Instagram and WhatsApp, is the company’s latest attempt to catch up in the global artificial intelligence race. By Eli Tan Reporting from San ...

Mindgard used a simple “restore this image” prompt (with no image attached) to see how easily ChatGPT could be steered into unsafe territory. An adversarial testing researcher named Jim Nightingale ...

There has been a sharp rise in so-called "nudification" technology. These AI-powered tools can generate realistic fake images and videos that depict people as undressed, often without their knowledge ...

SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance Clinical trial sites activated for GB-4362 (MMAE neutralizer); first patient dosing is expected in ...

Blake has over a decade of experience writing for the web, with a focus on mobile phones, where he covered the smartphone boom of the 2010s and the broader tech scene. When he's not in front of a ...

If vanilla AI image generators leave you feeling underwhelmed, it's time to play with the spicy stuff. I put the most popular NSFW options to the test so you can find the one that really hits the mark ...

With Claude enjoying a moment of newfound popularity among regular people, Anthropic is previewing an update designed to make its chatbot better at explaining some concepts. Starting today, Claude can ...

Generate:Biomedicines (NASDAQ: GENB), the drug developer focused on creating immunology and inflammation (I&I) and oncology treatments through its own artificial intelligence (AI)-based platform, has ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...